NEW DATA RELEASED ON EVARREST® FIBRIN SEALANT PATCH AS A HEMOSTATIC ADJUNCT IN AORTIC RECONSTRUCTION SURGERY
Ethicon, Inc. | March 05, 2016
Ethicon* today announced new data from a global cardiovascular (CV) Phase III clinical trial of the EVARREST® Fibrin Sealant Patch. Seventy five percent of patients treated during aortic reconstruction surgery with EVARREST® achieved hemostasis on the first attempt within three minutes and maintained hemostasis throughout the duration of the surgery, as compared to 45 percent for those treated with Baxter’s TachoSil®. Results from this investigational study will be presented at The Houston Aortic Symposium.